KindredBio has made public results of a test study on KIND-030, a chimeric, high-affinity monoclonal antibody targeting the virus, Canine Parvovirus.
The study focused on 12 dogs. Four were treated prophylactically and two were treated after the infection was well established. The remaining six were given placebos. All six that were treated survived, while all those given placebos died.
“We are pleased with the positive study results and are targeting approval of this product candidate by late 2020 or early 2021,” says KindredBio CEO Richard Chin.